{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:59:29Z","timestamp":1781020769550,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcyt.2026.102822","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:52:48Z","timestamp":1775231568000},"page":"102822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric antigen receptor\u2013natural killer cell therapy in first-relapse epithelial ovarian cancer: an early health-economic evaluation in the Netherlands"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2051-7301","authenticated-orcid":false,"given":"Abril","family":"Seyahian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirre","family":"Scholte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Gravesteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra L.M.","family":"Zusterzeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1228-5002","authenticated-orcid":false,"given":"Paul K.J.D.","family":"De Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7176-6156","authenticated-orcid":false,"given":"Anna","family":"de Goede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop H.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud L.M.","family":"Bekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella Beatrix","family":"Ottevanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3998-687X","authenticated-orcid":false,"given":"Harry","family":"Dolstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2579-1561","authenticated-orcid":false,"given":"Janneke P.C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102822_bib0001","unstructured":"Cancer TODAY. IARC Globocan 2022 (version 1.1). Available from: https:\/\/gco.iarc.who.int. Accessed March 14, 2025."},{"key":"10.1016\/j.jcyt.2026.102822_bib0002","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/CCO.0000000000000759","article-title":"Immunotherapy in rare ovarian cancer","volume":"33","author":"Laga","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.03.022","article-title":"An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations","volume":"146","author":"Salani","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0004","unstructured":"ESMO Gynaecological cancers pocket guideline 2024, European Society for Medical Oncology (ESMO). 2024."},{"key":"10.1016\/j.jcyt.2026.102822_bib0005","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1200\/JCO.19.00314","article-title":"Advances in the management of platinum-sensitive relapsed ovarian cancer","volume":"37","author":"Bouberhan","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0006","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12905-025-03904-y","article-title":"Analysis of global ovarian cancer disease burden and its changing trend from 1990 to 2021","volume":"25","author":"Gui","year":"2025","journal-title":"BMC Women's Health"},{"key":"10.1016\/j.jcyt.2026.102822_bib0007","doi-asserted-by":"crossref","first-page":"1308143","DOI":"10.3389\/fimmu.2023.1308143","article-title":"Ovarian cancer treatment and natural killer cell-based immunotherapy","volume":"14","author":"Fan","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0008","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ygyno.2020.03.020","article-title":"Harnessing natural killer cells for the treatment of ovarian cancer","volume":"157","author":"Hoogstad-van Evert","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0009","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ygyno.2025.11.006","article-title":"Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: results of the phase 1 INTRO-01 trial","volume":"204","author":"Hoogstad-van Evert","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0010","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"111","author":"Sarkar","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102822_bib0011","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462325100123","article-title":"Defining early health technology assessment: building consensus using Delphi technique","volume":"41","author":"Grutters","year":"2025","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jcyt.2026.102822_bib0012","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1017\/S0266462320000756","article-title":"On the integration of early health technology assessment in the innovation process: reflections from five stakeholders","volume":"36","author":"Tummers","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jcyt.2026.102822_bib0013","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jval.2023.03.009","article-title":"Frameworks for health technology assessment at an early stage of product development: a review and roadmap to guide applications","volume":"26","author":"Rodriguez-Llorian","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.jcyt.2026.102822_bib0014","doi-asserted-by":"crossref","first-page":"575","DOI":"10.15171\/ijhpm.2019.36","article-title":"Problems and promises of health technologies: the role of early health economic modeling","volume":"8","author":"Grutters","year":"2019","journal-title":"Int J Health Policy Manag"},{"key":"10.1016\/j.jcyt.2026.102822_bib0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2017.10.030","article-title":"No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands","volume":"88","author":"Timmermans","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jcyt.2026.102822_bib0016","unstructured":"CBS Deaths; underlying cause of death (shortlist), sex, age. 2024. Available from: https:\/\/opendata.cbs.nl\/statline\/#\/CBS\/en\/dataset\/7052eng\/table?ts=1719475895621. Accessed March 1, 2025."},{"key":"10.1016\/j.jcyt.2026.102822_bib0017","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0018","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0019","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0020","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2025.03.018","article-title":"ENGOT-OV16\/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety","volume":"195","author":"Matulonis","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0021","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102822_bib0022","unstructured":"Rohatgi, A. (2024). WebPlotDigitizer (Version 4.7) [Computer software]. https:\/\/automeris.io\/WebPlotDigitizer"},{"key":"10.1016\/j.jcyt.2026.102822_bib0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0024","series-title":"RStudio: Integrated Development Environment for R","year":"2024"},{"key":"10.1016\/j.jcyt.2026.102822_bib0025","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jcyt.2026.102822_bib0026","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdr441","article-title":"Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial","volume":"23","author":"Gladieff","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0027","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102822_bib0028","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcyt.2020.03.432","article-title":"What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings","volume":"22","author":"Ten Ham","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102822_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230909","article-title":"Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands","volume":"15","author":"Schneider","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102822_bib0030","series-title":"Costing manual: Methods and Reference Prices for Economic Evaluations in Healthcare","author":"Hakkaart-van Roijen","year":"2024"},{"key":"10.1016\/j.jcyt.2026.102822_bib0031","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1524-4733.2009.00515.x","article-title":"QALYs: the basics","volume":"12 Suppl 1","author":"Weinstein","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jcyt.2026.102822_bib0032","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/lary.23943","article-title":"Health economic evaluation: important principles and methodology","volume":"123","author":"Rudmik","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jcyt.2026.102822_bib0033","doi-asserted-by":"crossref","first-page":"101293","DOI":"10.1016\/j.gore.2023.101293","article-title":"Health state utility and health-related quality of life measures in patients with advanced ovarian cancer","volume":"50","author":"van Stein","year":"2023","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.jcyt.2026.102822_bib0034","unstructured":"Zorginstituut Nederland. Verslag van de vergadering van de Wetenschappelijke Adviesraad (WAR) over niraparib (Zejula\u00ae). 2021."},{"key":"10.1016\/j.jcyt.2026.102822_bib0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","article-title":"AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users","volume":"34","author":"Vemer","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jcyt.2026.102822_bib0036","unstructured":"Netherlands Cancer Registry (NCR). Integraal Kankercentrum Nederland (IKNL) 2023. Available from: https:\/\/iknl.nl\/en\/NCR. Accessed March 13, 2025."},{"key":"10.1016\/j.jcyt.2026.102822_bib0037","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40273-019-00810-8","article-title":"Severity-adjusted probability of being cost effective","volume":"37","author":"Versteegh","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jcyt.2026.102822_bib0038","series-title":"Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer","year":"2013"},{"key":"10.1016\/j.jcyt.2026.102822_bib0039","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0040","unstructured":"Scottish Medicines Consortium. Bevacizumab (Avastin\u00ae) 25 mg\/mL concentrate for solution for infusion: SMC No. 853\/13. Glasgow: Scottish Medicines Consortium; 2013."},{"key":"10.1016\/j.jcyt.2026.102822_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195134","article-title":"First- and second-line bevacizumab in ovarian cancer: a Belgian cost-utility analysis","volume":"13","author":"Neyt","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2026.102822_bib0042","series-title":"(KCE Reports 285)","article-title":"Bevacizumab in the treatment of ovarian cancer","author":"Neyt","year":"2017"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102822_bib0043","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jcyt.2025.04.060","article-title":"Shaping the future of cell and gene therapy workforce development: training of cell therapy processing personnel - perspectives from the International Society for Cell & Gene Therapy Lab Practices Committee","volume":"27","author":"Maryamchik","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102822_bib0044","series-title":"Herbeoordeling PARP-remmers voor de behandeling van 4 typen kanker","year":"2024"},{"key":"10.1016\/j.jcyt.2026.102822_bib0045","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonzalez-Martin","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0046","series-title":"NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 2.2026","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102822_bib0047","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0048","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2026.102822_bib0049","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-024-03826-w","article-title":"Promising new drugs and therapeutic approaches for treatment of ovarian cancer-targeting the hallmarks of cancer","volume":"23","author":"Hillmann","year":"2025","journal-title":"BMC Med"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:20:43Z","timestamp":1781018443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926007838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1465324926007838"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102822","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor\u2013natural killer cell therapy in first-relapse epithelial ovarian cancer: an early health-economic evaluation in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102822"}}